Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects

Summary

The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .

Timeline

Start

2020-12-22

Primary completion

2021-01-19

Completion

2021-02-07

Drugs

Indications